Parkinson disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. It has been proposed that dysfunction of the ubiquitin proteasome system plays an important role in the pathogenesis of Parkinson disease, but the mechanisms underlying ubiquitin proteasome system-related neuron degeneration are unknown. Here, we demonstrate that the proteasome inhibitor lactacystin induces phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, the release of cytochrome c, activation of both caspase-9 and caspase-3, and sequential apoptosis of dopaminergic neurons in vitro. Most of these effects can be attenuated by the JNK inhibitor SP600125. Furthermore, infusion of lactacystin in rats in vivo also leads to phosphorylation of JNK before nigral neuron loss; chronic administration of SP600125 also blocks this loss. These results indicate that JNK is involved in proteasome inhibition-induced dopaminergic neuron degeneration through caspase-3-mediated apoptotic pathways, suggesting that this kinase may be a therapeutic target for the prevention of substantia nigra pars compacta degeneration in Parkinson disease patients.
INTRODUCTION
Parkinson disease (PD) is a progressive neurodegenerative disorder that afflicts 1% to 2% of the population older than 65 years. It is characterized by a loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) region of the midbrain, which is followed by depletion of dopamine (DA) in the striatum and sequentially results in movement abnormalities as the principal clinical manifestation (1Y3). To date, the pathogenesis of PD remains poorly understood, and no cures are available for the disease.
It is believed that both environmental and genetic factors contribute to PD pathogenesis (4Y7). Circumstantial evidence suggests that protein mishandling (i.e. abnormal aggregation or degradation or phosphorylation) (3, 8Y11) and dysfunction of the ubiquitin proteasome system (UPS) are key molecular pathological processes that lead to PD (2, 7, 10) . It is known that mutations in genes associated with UPS can cause familial PD, and various components of the UPS are found in Lewy bodies, the pathological hallmarks of PD (2, 7, 8, 10) . Furthermore, several pathological processes that are tightly linked with PD (i.e. oxidative stress, mitochondrial defects, and protein aggregation) can impair proteasomal functions (2, 3, 9, 10) . A significant decrease in proteasome activities is found in the midbrain of sporadic PD patients (10) . Moreover, application of proteasome inhibitors to neurons in vitro (12Y14) and in vivo (10, 15, 16) can reproduce some cardinal pathological features of PD, although the rodent model produced by systematic administration of proteasome inhibitor PSI is controversial (17) . Therefore, although the molecular and cellular mechanisms underlying UPS impairment-induced DA neuron degeneration remain to be defined, in vitro and in vivo models provide valuable tools for the study of the pathophysiology of PD and for developing novel therapies for this devastating disease.
The role of apoptosis in PD is still controversial. Some studies suggest the involvement of apoptosis in the pathogenesis of PD (13, 18, 19) , whereas others indicate that necrosis or other forms of death can also play a role (20Y22). In the present study, we investigate DA neuron degeneration induced by proteasome inhibition and whether it is preceded by the activation of c-Jun N-terminal kinase (JNK), cytochrome c (Cyt C), and caspase pathways.
c-Jun N-terminal kinase is a member of the mitogenactivated protein kinase (MAPK) family and has been found to have a role in DA neuron apoptosis (23Y26). c-Jun Nterminal kinase inhibitors have been shown to prevent DA neuron degeneration in several in vitro and in vivo models (24, 27Y30) . Numerous studies in cell lines and primary neuron cultures have shown that proteasome inhibition can elicit endoplasmic reticulum (ER) stress (31) and activate apoptosis signal-regulating kinase 1 (32) , which in turn can activate the JNK pathway (32, 33) . Caspase-3 is downstream to the JNK signaling pathway (26, 34) . It has been reported that JNK-related apoptosis in neurons is mediated by c-Jun-related transcription of proapoptotic factors such as Copyright @ 2008 American Academy of Child and Adolescent Psychiatry. Unauthorized reproduction of this article is prohibited.
Bim and Cox-2, and by a mitochondria-associated apoptotic pathway (27, 30, 34Y36) . It remains to be determined, however, whether the JNK signaling pathway is involved in the proteasome inhibition-induced DA neuron degeneration and whether the caspase-3-associated intrinsic apoptotic pathway plays a role.
We used the proteasome inhibitor lactacystin in the SH-SY5Y cell line and ventral mesencephalon (VM) cells in vitro and injected it into rat medial forebrain bundles (MFB) in vivo as models for determining whether JNK could be involved in proteasome inhibition-induced DA neuron degeneration through the caspase-3 and other mediated mitochondria-associated apoptotic pathways in PD.
MATERIALS AND METHODS

Cell Cultures
Human dopaminergic neuroblastoma SH-SY5Y cells (Cell Bank of Chinese Academy of Sciences, Shanghai, China) were maintained in DF12 medium (Sigma, St Louis, MO) containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 50 U/mL penicillin, and 50 mg/mL streptomycin at 37-C in a humidified 5% carbon dioxide atmosphere. For differentiation, the cells were exposed to 10 KM all-trans-retinoic acid (Sigma) in medium containing 2% fetal bovine serum for 48 hours. Primary mesencephalic neuron-enriched cultures were prepared from E14 Sprague Dawley rat embryos as previously described (37) . Primary VM cells were allowed to grow in a serum-free medium for 7 days in vitro before experimental treatments.
Animals and Surgical Procedures
Male Sprague Dawley rats weighing 200 to 250 g (Animal Center, Chinese Academy of Science, Shanghai, China) were treated in accordance with the Guidelines on the Care and Use of Laboratory Animals at Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences. For stereotaxic injection, rats were anesthetized with chloral hydrate (400 mg/kg, intraperitoneally) and mounted on a benchmarker stereotaxic apparatus (myNeurolab, St Louis, MO) in a sterilized chamber. Each animal received an injection of either 3 Kg lactacystin (Calbiochem, Beeston, Nottingham, United Kingdom) in 2 KL vehicle (0.1% dimethyl sulfoxide [DMSO]) or vehicle as control into the right MFB at a flow rate of 1 KL/minute (anterioposterior to bregma (AP), j2.2 mm; lateral to the midline (ML), j1.5 mm from bregma; dorsoventral (DV), j8.15 mm from the surface of the dura) (38) . We used a miniosmotic pump to chronically administer the JNK inhibitor SP600125 (Calbiochem), which was dissolved in 200 KL of vehicle containing artificial cerebrospinal fluid ([in mM] 147 NaCl, 3 KCl, 1.2 CaCl 2 , 1.1 MgSO 4 , 0.4 Na 2 HPO 4 , 2.1 NaHCO 3 , 2.7 glucose; pH 7.2) and 3% DMSO to a final concentration of 1.5 KM. Brain Infusion Kit II and Alzet miniosmotic pumps (Durect Corp, Cupertino, CA) were prepared according to the manufacturer's instructions. A cannula was implanted into the left lateral ventricle of rats (AP, j1.0 mm; LV, j1.5 mm; DV, j3.5 mm) and affixed to the skull surface using instant adhesive gel. Minipumps were implanted into a subcutaneous pocket between the scapulae for 4 weeks, and chemicals were delivered continuously at a rate of 0.25 KL/hour.
Experimental Group Treatments
In the SH-SY5Y cell model, the experiment was divided into 4 groups: lactacystin-treated (LC), normal controls (CON), SP600125 + lactacystin (SPLC), and SP600125 alone (SPNC). Cells in the LC groups were treated with 5 KM of lactacystin that was freshly prepared by dissolving it in DMSO and diluted with culture medium. Cells in the CON group were treated with vehicle (0.1% DMSO). Cells in the SPLC group were pretreated with 10 KM of SP600125 1 hour before the addition of lactacystin; cells in the SPNC group were treated with SP600125 and vehicle. The group setting and treatments in VM cell cultures were the same as SH-SY5Y cultures, except that SP600125 was pretreated with 1, 5, or 10 KM.
In the rat model, lactacystin (LC group) or vehicle (CON group) was administered unilaterally into the MFB. To test the protective effects of the JNK inhibitor, SP600125 was administered into the cerebral ventricle (intracerebroventricular [ICV]) 1 hour before lactacystin injection into MFB (SPLC group); vehicle ICV was used as the control. The experimental animals were killed at various time points for further histological and biochemical analyses.
RNA Extraction and Reverse Transcription Polymerase Chain Reaction
The total RNA extraction and the reverse transcription polymerase chain reaction (PCR) were performed as previously described (37) . The primers used for PCR assays (Table 1) were purchased from Invitrogen Biotec (Shanghai, China). Polymerase chain reaction products were run on a 2% agarose gel (for Xbp1, on 8% PAGE) and the semiquantitative assays were performed as previously described (37) .
Histological Procedure and Immunostaining
Cultures were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer saline ([PBS] pH 7.4) for 20 minutes at 4-C before assays. Rats were deeply anesthetized with chloral hydrate and perfused with ice-cold 0.1 M PBS (pH 7.4) at specific time points. The brains were then immediately removed, placed on ice, transected coronally at the posterior optic chiasm (j1.5 mm from bregma). Striatal tissues were rapidly dissected out and stored at j80-C until biochemical analysis. Midbrain blocks were rapidly dissected at the infundibular stem and fixed in 4% paraformaldehyde for 1 day, followed by dehydration in 30% sucrose for 2 days at 4-C, and then stored in OCT compound (Tissue-Tek, Sakura, Japan) at j80-C until serial coronal sections (12 Km) through the entire midbrain were cut on a cryostat (LEICA CM 1850, Germany).
For immunohistochemical staining, culture coverslips or brain sections were treated with 1% hydrogen peroxide and then incubated in a blocking solution (4% horse serum and 0.3% Triton-X-100 in PBS, pH 7. To determine the lactacystin-induced cell injury in the SH-SY5Y cell line, cultures on plates were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide ([MTT] 0.5 mg/mL, Sigma) for 3 hours at 37-C and then harvested in a lysis buffer (10% sodium dodecyl sulfate, 50% DMSO, 0.4% HAc, 0.4% 1N HCl). The optical densities at 560 nm were measured sequentially by transferring 100-KL aliquots to 96-well plates using a MK3 microplate reader (Thermo LabSystems, Vantaa, Finland). The viable cell value was expressed as the ratio of optical densities to that of the control group. To evaluate survival rate of DA neurons in cultures, total TH-positive cells were counted in triplicate at a magnification of 160Â from 8 optical fields in a blinded manner. The values were expressed as the ratio of TH-positive neurons in each experimental group to that in control groups. In the animal study, TH-positive neurons in the SNc were counted every fifth section throughout the entire midbrain at a magnification of 100Â. The SNc was outlined using anatomical landmarks (see Supplementary figure) . After all sections were counted, the total number of TH-positive neurons on the injection side was transformed as the ratio to that on the uninjected side of the SNc.
To assess the percentage of double-stained DA neurons (TH/phosphor-c-Jun and TH/c-caspase-3) in cultures, more than 100 TH-positive cells per coverslip were observed at a magnification of 640Â in a blind way, and photographed under the fluorescent microscope equipped with CCD digital camera. Apoptotic cells were defined as those with condensed fragmented nuclei. To assess the percentage of double-stained DA neurons (TH/phosphor-JNK) in SNc, the phosphor-JNKstained cells were counted in total TH-positive neurons from the outlined SNc region according to the anatomical landmarks (see Supplementary figure) under the immunofluorescence microscope at a magnification of 320Â (38) . Data were then transformed as the percentage of the total number of TH-positive cells, as previously described (37) .
Western Blot Analysis
Differentiated SH-SY5Y cells were harvested at various time points after experimental treatments and lysed on ice for 20 minutes in freshly prepared modified radioimmunoprecipitation assay buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP40, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM Na 2 VO 4 , 1 mM NaF, 1 mM PMSF, aprotinin, leupeptin 5 mg/mL each; pH 7.4). Brain tissues were homogenized on ice in the modified radioimmunoprecipitation assay using a supersonic crasher (ScienTZ Biotec, Ningbo, China). The subsequent steps for the Western blotting were as previously described (31) except that 5% bovine serum albumin in Tris-buffered saline (pH 7.4) was used as blocking solution for detecting phosphorylated proteins. The primary antibodies were used at concentrations as follows: (JNK, phosphor-JNK, c-Jun, phosphor-c-Jun, caspase-9, c-caspase-3, 1:1000, Cell Signaling; TH, 1:6000 and A-actin, 1:3000, Sigma). Detection of the Western blotting followed the manufacturer's instructions in the SuperSignal Detection Kit (Pierce, Rockford, IL).
Cytochrome c Release Assays
To test the Cyt C release in cell cultures, cytoplasmic proteins were harvested in an ice-cold lysis solution for 10 minutes (HEPES-KOH 20 mM, KAc 10 mM, NaAc 5 mM, MgAc 2 2 mM, EGTA 1 mM, digitonin 200 mg/mL; pH 7.3). The supernatants were collected by centrifugation at 10,000 Â g for 15 minutes at 4-C, and the sequential steps for Western assays were the same as previously mentioned, except that primary and secondary antibodies were anti-Cyt C (1:8000; Sigma) and anti-sheep horseradish peroxidaseconjugated IgG (Chemicon, Temecula, CA), respectively. To examine the Cyt C release in DA neurons, VM cultures after experimental treatments were incubated with MitrotracRed (100 nM; Molecular Probes, Eugene, OR) at 37-C for 30 minutes. After twice washing with PBS, the cells were fixed with 4% paraformaldehyde and followed by a double immunofluorescent staining for TH and Cyt C (TH, 1:2000; Cyt C, 1:800) as described previously. An anti-sheep Cyt C-conjugated IgG (1:800; Jackson Laboratories, Bar Harbor, ME) was used to label Cyt C. Fluorescence signals were detected at 640Â (oil immersion) using a confocal microscope (Leica, TCS-SP2, Germany).
Detection of DA Levels by High-Performance Liquid Chromatography
Dopamine and its metabolites were measured by highperformance liquid chromatography with electrochemical detection, as previously described (15); the composition of the mobile phase was as in the previous study (37) . Monoamine concentrations were calculated by comparison of peak height ratios of the samples with those of standards FIGURE 2. Lactacystin treatment induces endoplasmic reticulum stress in the SH-SY5Y cell model. Reverse transcription polymerase chain reaction (RT-PCR) analysis shows that messenger RNA levels of Bip, Chop, and spliced Xbp1 (arrows) were increased after lactacystin treatment at various time points. *, p G 0.05; **, p G 0.01 vs untreated groups (CON) by independent t-test; n = 5. using Powerchrom software (PowerLab, Australia), and then expressed as the ratio of the concentrations at the intact side.
Statistical Analysis
All data were expressed as means T SEM. Independent t-test or 1-way analysis of variance between groups followed by post hoc Bonferroni tests were used for the analysis of data via the SPSS 10.0 software packages (SPSS, Inc, Chicago, IL). The criterion for statistical significance was set at p G 0.05.
RESULTS c-Jun N-Terminal Kinase Inhibition Prevents the Lactacystin-Induced DA Neuron Apoptosis In Vitro
The human-derived neuroblastoma cell line SH-SY5Y and primary VM cultures have been widely used to investigate the molecular mechanisms underlying DA neuron degeneration induced by neurotoxins (24, 28) and by proteasome inhibition (12Y14, 31). In differentiated SH-SY5Y cells, lactacystin exposure (5 KM) significantly decreased cell viability, as determined by MTT assay (LC12H, 12.3%; LC24H, 14.6%, p G 0.05 vs CON, Fig. 1A) , and increased the rate of apoptosis as detected by the nuclear morphology stained with Hoechst 33258 (LC12H, 10.5%; LC24H, 12%, p G 0.01 vs CON, Figs. 1B, C) . In the presence of the JNK inhibitor SP600125 (SPLC, 10 KM), the lactacystin-induced cell injury and apoptosis were significantly attenuated, as shown by the MTT assay (SLC12H, 7.7%; SLC24H, 12%, p G 0.05 vs LC, Fig. 1A) an increase in the apoptotic rate of TH-positive cells (LC, 16.6%, p G 0.01 vs CON, Fig. 1F ) were shown in lactacystintreated VM cultures. Pretreatment with SP600125 at various concentrations (S1LC, 1 KM; S5LC, 5 KM; S10LC, 10 KM) also promoted DA neuron survival (S1LC, 73.4%, p G 0.05 vs LC; S5LC, 82.4%; S10LC, 83.4%, p G 0.01 vs LC, Figs. 1D, E) and suppressed the apoptotic rate in a dosedependent manner (S1LC, 11.5%, p G 0.05 vs LC; S5LC, 9.2%; S10LC, 6.9%, p G 0.01 vs LC, Fig. 1F ). These protective effects of SP600125 were not shown in cells pretreated with the p38MAPK inhibitor SB203580 (1, 5, and 10 KM), and SP600125 per se for 24 hours did not significantly affect the growth of TH-positive cells, as previously reported (39) (data not shown). These results suggest that apoptosis plays a role in lactacystin-induced DA cell injury, and that the JNK pathway is specifically involved in the apoptotic process. It has been reported that proteasome dysfunction can induce ER stress, a signaling upstream to JNK activation (32, 33) . We tested whether ER stress was evoked in the lactacystin-treated SH-SY5Y cells as we had previously reported in VM cultures (31) . Using semiquantitative reverse transcription PCR analysis, we found that after lactacystin treatment, the messenger RNA levels of several ER stressrelated genes were increased. These included immunoglobulin heavy chain-binding protein (Bip, 1.5-fold at 5 hours, 1.8-fold at 12 hours, p G 0.05 vs CON), CCAAT/enhancerbinding protein-homologous protein (Chop, 2.2-fold at 5 hours, p G 0.05 vs CON; 2.6-fold at 12 hours, 2.8-fold at 24 hours, p G 0.01 vs CON), and spliced X-box-binding protein 1 (sXbp1, 2.5-fold at 2 hours, 2-fold at 5 hours, p G 0.05 vs CON; Fig. 2 ). These results suggest that proteasome inhibition can elicit ER stress in DA neurons at an early stage, and that the JNK signaling pathway seems to be activated in this in vitro model.
We next analyzed the phosphorylated protein levels of both JNK and its substrate c-Jun in SH-SY5Y cells. As shown in Figures 3A, BiYii, lactacystin treatment markedly increased the levels of phosphor-JNK (LC5H, p G 0.05 vs CON; LC12H, p G 0.01 vs CON) and phosphor-c-Jun-ser63 (LC5H, p G 0.05 vs CON; LC12H, p G 0.01 vs CON; LC24H, p G 0.05 vs CON). A similar increase was also seen with another substrate of JNK, P53 (Ser15) (data not shown). SP600125 pretreatment (10 KM) alone did not affect phosphorylation of JNK (SPLC5H, SPLC12H, p 9 0.05 vs LC), but it significantly attenuated the lactacystin-induced increase in levels of phosphor-c-Jun (SPLC5H, p G 0.05 vs LC; SPLC12H, SPLC24H, p G 0.01 vs LC, Figs. 3A, BiYii). These results indicate that the JNK pathway is activated under the condition of proteasome inhibition.
It has been reported that JNK activation is involved in the apoptotic process in various models of PD (24Y26, 30, 34) , and that the mitochondria apoptotic machinery mediates the neuronal injury induced by proteasome inhibition (40). We then tested the possible link between JNK activation and the intrinsic apoptotic pathway in vitro. We found that exposure to lactacystin for 12 hours led to a dramatic increase in c-caspase-3 levels (LC12H, p G 0.01 vs CON). This effect was significantly blocked by pretreatment with SP600125 (SLC12H, p G 0.01 vs LC, Figs. 3A, Biii). We further examined the protein levels of the cleaved caspase-9 (c-caspase-9) and the cytosolic Cyt C after lactacystin treatment. As shown in Figures 3C, D CON, Fig. 4G ). These changes were significantly blocked by SP600125 pretreatment (5 KM, SPLC12H, 12.5%, Fig. 4E, SPLC24H, 16 .3%, p G 0.05 vs LC, Fig. 4G ).
Because we previously found caspase-3 activation in lactacystin-treated DA neurons (31), we further determined the effect of JNK inhibition on caspase-3 activation. Compared with the controls (CON, Fig. 5A ), the c-caspase-3 level in TH-positive cells was increased after lactacystin treatment (LC, Figs. 5A, B; LC12H , 10%, p G 0.05 vs CON; LC24H, 25.7%, p G 0.01 vs CON, Figs. 5C, D) . Similar suppression on the caspase-3 activation in DA cells was shown in the SP600125 pretreatment groups (SPLC, Fig. 5A ; SPLC12H, 5.8%; SPLC24H, 12.7%, p G 0.05 vs Figs. 5C, D) .
Finally, we observed the lactacystin-induced Cyt C release in DA cells using triple-staining techniques to label the mitochondria, TH, and Cyt C, and used Western blot assay to detect Cyt C in the cytoplasm. In the vehicletreated group (CON), Cyt C was displayed as bright punctate staining and was localized to mitochondria (CON, Figs. 6A1YA4). In contrast, in the lactacystin treatment group (for 12 hours), the neurites were lost from some TH-positive cells, and Cyt C showed a diffuse cytosolic staining pattern; the Cyt C in mitochondria was weakly immunostained (LC, Figs. 6B, D1YD4), likely indicating a redistribution of this protein from the mitochondria accompanying cell injury after lactacystin treatment. In addition, Western blots showed that Cyt C in the cytoplasm was increased after lactacystin treatment (Figs. 6E, F) , and these lactacystin-induced alternations were alleviated by SP600125 pretreatment (SPLC, Figs. 6C1YC4, E, F). These results indicate that under the conditions of proteasome inhibition, caspase-3-related intrinsic apoptosis is subsequent to JNK activation and participates in DA neuronal injury in VM cultures.
Lactacystin Activates JNK Before Nigral DA Neuron Injury and JNK Inhibitor Prevents DA Neuron Loss
To determine whether proteasome inhibition impairs the nigral-striatal DA neural system and whether JNK activation plays a role, we first administered lactacystin (3Kg) unilaterally into rat MFB by stereotaxic injection and then determined both the striatal DA level and the number of THpositive cells in the SNc from 2 to 4 weeks after lactacystin injection (LC2-4W). Compared with the intact side (Fig. 7C) , there was a sustained loss of TH-positive cells in the SNc on the lesioned side (LC3W, 21.8%; LC4W, 31.7%; p G 0.01 vs CON and LC1W; p G 0.05 vs LC2W, Figs. 7D, E) . Coincidently, the striatal levels of DA and its metabolites were decreased as shown by TH immunostaining (Fig. 7A,  B) and high-performance liquid chromatography assay (DA: LC3W, 69%, p G 0.05 vs CON; LC4W, 60%, p G 0.01 vs CON; homovanillic acid: LC3W, 74%, p G 0.05 vs CON; LC4W, 53%, p G 0.01 vs CON, Fig. 7F ), whereas 5-hydroxyindolacetic acid did not change significantly. This suggests that microinjection of lactacystin reproduced the impairment of nigral DA neural system in the rat.
We next determined whether JNK is involved in the lactacystin-induced nigral DA neuron injury by assaying JNK activation in nigral DA neurons after lactacystin injection. Dual immunostaining of TH and phosphor-JNK on brain sections showed the increased phosphor-JNK in TH-positive cells, which could be detected at 1 to 2 weeks after injection (LC1W, 9%, Figs. 8B, D, K; LC2W, 11.7%; p G 0.01 vs CON, Figs. 8A, C, K). Such increase in the percentage of colocalized cells was sustained to 3 to 4 weeks after lactacystin injection (LC3W, 9.2%; p G 0.05 vs LC2W, p G 0.01 vs CON; LC4W, 14.5%, p G 0.05 vs LC3W, p G 0.01 vs CON, Figs. 8EYK). At 2 weeks after lactacystin injection, Western blot assays on brain tissues showed an , whereas TH levels in the SN were unaffected, suggesting that JNK activation occurs before the nigral DA neuron loss. We finally tested whether intervention of JNK activation protected the lactacystin-induced nigral DA neuron injury. By chronic delivery of SP600125 ICV for 4 weeks, we found that the lactacystin-induced decrease of striatal DA and metabolite levels were remarkably attenuated (Figs. 8N1, N2; Table 2 ), and the loss of TH-positive neurons in the SNc was significantly prevented (LC, 65.4%; SPLC, 79.6%; p G 0.05 vs LC, Figs. 8O, P). These results indicate that the JNK signaling pathway is involved in proteasome inhibition-induced nigral DA neuron injury.
DISCUSSION
The ubiquitin proteasome system dysfunction has been proposed to play an important role in the pathogenesis of PD (2, 7Y9, 12) , and apoptosis is likely to participate in the process of progressive DA loss (13, 18, 19) . How UPS dysfunction elicits apoptosis in DA neurons and whether there is any common signaling pathway that can initiate the neurodegenerative process in PD are not understood. Based on our UPS impairment models in vitro and in vivo, we found in the present study that JNK activation is a critical step in the proteasome inhibition-induced DA neuron injury through a caspase-3-associated intrinsic apoptotic pathway. This finding in cell and rodent models of proteasome inhibition supports the notion that this protein kinase may have a role in DA neuron degeneration (3, 11) . Other studies using animal models induced by paraquat or 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine showed that the JNK signaling pathway is activated, and that DA neuron loss can be prevented by JNK inhibition (24, 27, 29) . This suggests that this JNK signaling pathway may serve as a converging initiator for DA neuron degeneration in these models. It is not known, however, whether the alteration of the JNK signaling pathway is the key element contributing to the pathogenesis of PD. More studies are necessary to verify this finding before considering it as a potential therapeutic target for PD.
c-Jun N-terminal kinase, also known as stress-activated protein kinase, participates in pathological events such as cell stress and apoptosis (11, 26) . c-Jun N-terminal kinase can also integrate multiple biological signals and mediate various physiological functions (11, 26) , including the differentiation and maturation of DA neurons (39, 41) . Previous studies have indicated a role for JNK in the pathophysiology of PD. For example, an increased level of phosphorylated JNK is found in the SN with overactivation of c-Jun in the nigral DA neurons of PD patients (26) . In rodent models, nigral DA neuron degeneration induced by neurotoxins, such as 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine, paraquat (24, 26, 27, 29) , or axotomy lesion of MFB, has been shown to be mediated by the JNK signaling pathway (30) . In DA cell lines SN4741 (23), SH-SY5Y (28, 42) and primary VM and microglia cultures (25, 43) , JNK signaling pathway is involved in the DA neuron injury in response to mitochondrial dysfunction and oxidative stress. In the present study, we found that proteasome inhibition activated the JNK signaling pathway, and that these effects were prevented by JNK inhibition, suggesting that this signaling pathway might serve as a converging initiator of DA neuron degeneration in these models.
Similar to other MAPK pathways, JNK activation involves a 3-tier step known as MKKK-MKK-MAPK cascades. Five classes of MKKK in the JNK signaling pathway have been identified among which mixed lineage kinases and apoptosis signal-regulating kinase 1 have been intensely studied (11, 26, 30, 34) . In our in vitro and in vivo models, it is still unclear how proteasome inhibition activates JNK signal. It has been reported that radical oxidative species induced by neurotoxins (23, 24, 27Y29) and oxidative stressors (23, 28, 42, 44) can activate JNK. Recent studies have shown that ER stress and unfold protein stress can also activate JNK through either apoptosis signal-regulating kinase 1 or inositol-requiring enzyme 1 (11, 26, 28, 32, 33, 45) . In addition, JNK activity is regulated by diverse scaffold proteins including JNK-interacting protein 1 (29), SH3 (POSH) (45) , and postsynaptic density protein 95 (46) , and SH3 (POSH) (47) . Proteasome inhibition can activate ER stress-radical oxidative species signaling cascades (28, 45) and disrupt the degradation of postsynaptic density protein 95 and POSH, both of which are able to upregulate JNK activity (46, 47) . These factors may collectively contribute to JNK activation in the UPS impairment models.
c-Jun N-terminal kinase participates in the mitochondrial impairment-induced caspase-3 activation (23, 24, 29) and mediates the oxidative stress-induced intrinsic apoptosis in DA cells (44) . It has also been reported to play a role in the proteasome inhibition-induced apoptosis in several cell models (40, 48, 49) . Here, we have demonstrated that JNK is involved in the proteasome inhibition-induced DA neuron degeneration through the intrinsic apoptotic pathway, thereby supporting the notion that mitochondria-related apoptosis may contribute to the loss of nigral DA neurons in PD (19) . So far, the exact mechanism through which JNK elicits the intrinsic apoptosis under conditions of proteasome inhibition is unclear, but it has been shown that many components of the JNK signaling pathway are localized at the mitochondrial membrane (35) . Activated JNK induces Cyt C release through the phosphorylation of Bim and Bad as well as 14-3-3 (ser128) (26, 34, 36) . A BH3-only protein residing at the mitochondria in neurons, BIMEL, mediates neuronal cell death after being phosphorylated by JNK. Interestingly, while activating JNK and sequentially phosphorylating BIMEL, proteasome inhibition also blocks the degradation of Bim and phosphor-BIMEL (35, 50) . Because increased phosphor-JNK was shown in our experimental models, and it can affect apoptosis or cell cycle activation in neurodegenerative disease, we cannot rule out the possibility that cell cycle activation may occur simultaneously after proteasome inhibition. Our studies show, however, that the DA neuron loss followed by proteasome inhibition is accompanied by decreased survival of TH-positive cells in the SN, both at the DA level and in TH-positive fibers in the striatum. This suggests that the effect of apoptosis may overcome the cell cycle activation. Further studies are necessary to determine the role of cell cycle activation and its related pathways in the proteasome inhibition-induced DA neuron degeneration.
It is believed that targeting the initiative phase of apoptosis is better than the executive phase to prevent DA neuron degeneration. c-Jun N-terminal kinase inhibition has been proposed as a promising therapeutic target. A recent clinical Parkinson Research Examination of CEP-1347 Trial (PRE-CEPT) had a disappointing outcome (11) . CEP1347 is, however, a mixed lineage kinase inhibitor that is able to suppress JNK activation but has no effect on activated JNK (11), whereas the JNK-binding domains of JNK-interacting protein 1 and SP600125 prevent DA neuronal loss in various experimental systems (24, 26, 29, 30, 34) . SP600125 can specifically block the JNK pathway by inhibiting phosphorylation of its substrates while sparing other MAPKs. Application of SP600125 in vivo reduces the interaction between JNK and Bim, blocks the translocation of Bax to the outer membrane of mitochondria (35) , and inhibits the caspase-3 activation in DA neurons (24) , as well as inhibiting the activation of microglia (25, 43) . Interestingly, we recently found that microinjection of lactacystin in MFB activates the microglia in the SNc (51) , suggesting that the protection of SP600125 on nigral DA neuons in vivo may result from the inhibition of JNK in both DA neurons and microglia.
In conclusion, our findings demonstrate that JNK mediates proteasome inhibition-induced DA neuron degeneration through activating intrinsic apoptotic pathways and suggest that JNK activation may be a common upstream signal for the apoptotic processes in DA neurodegeneration. Thus, this kinase might be a potential therapeutic target for the prevention of DA neuron degeneration in PD.
